1. Home
  2. CTMX vs CPAC Comparison

CTMX vs CPAC Comparison

Compare CTMX & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • CPAC
  • Stock Information
  • Founded
  • CTMX 2008
  • CPAC 1949
  • Country
  • CTMX United States
  • CPAC Peru
  • Employees
  • CTMX N/A
  • CPAC N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • CPAC Building Materials
  • Sector
  • CTMX Health Care
  • CPAC Industrials
  • Exchange
  • CTMX Nasdaq
  • CPAC Nasdaq
  • Market Cap
  • CTMX 596.2M
  • CPAC 580.5M
  • IPO Year
  • CTMX 2015
  • CPAC 2012
  • Fundamental
  • Price
  • CTMX $3.64
  • CPAC $7.25
  • Analyst Decision
  • CTMX Strong Buy
  • CPAC Sell
  • Analyst Count
  • CTMX 6
  • CPAC 2
  • Target Price
  • CTMX $6.50
  • CPAC $6.95
  • AVG Volume (30 Days)
  • CTMX 3.9M
  • CPAC 19.5K
  • Earning Date
  • CTMX 11-06-2025
  • CPAC 10-28-2025
  • Dividend Yield
  • CTMX N/A
  • CPAC 6.91%
  • EPS Growth
  • CTMX 50.22
  • CPAC 20.27
  • EPS
  • CTMX 0.24
  • CPAC 0.15
  • Revenue
  • CTMX $113,631,000.00
  • CPAC $601,081,883.00
  • Revenue This Year
  • CTMX N/A
  • CPAC $9.96
  • Revenue Next Year
  • CTMX N/A
  • CPAC $1.70
  • P/E Ratio
  • CTMX $15.28
  • CPAC $9.56
  • Revenue Growth
  • CTMX N/A
  • CPAC 6.18
  • 52 Week Low
  • CTMX $0.40
  • CPAC $5.10
  • 52 Week High
  • CTMX $4.62
  • CPAC $7.57
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 50.34
  • CPAC 50.07
  • Support Level
  • CTMX $3.35
  • CPAC $7.16
  • Resistance Level
  • CTMX $4.45
  • CPAC $7.40
  • Average True Range (ATR)
  • CTMX 0.37
  • CPAC 0.19
  • MACD
  • CTMX -0.06
  • CPAC -0.02
  • Stochastic Oscillator
  • CTMX 30.00
  • CPAC 20.56

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About CPAC Cementos Pacasmayo S.A.A. (Each representing five)

Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.

Share on Social Networks: